Pharmaceutical Market Europe (@PMLiVEcom) header
Pharmaceutical Market Europe (@PMLiVEcom) profile picture

Pharmaceutical Market Europe

@PMLiVEcom

News & analysis of healthcare, pharma and biotech. Magazines, directories, profiles, jobs & awards.

 Surrey, UK
pmlive.com/pme
Joined June 2009
  • Tweets22.5K
  • Following3.3K
  • Followers15.6K
648Media
Photo by Pharmaceutical Market Europe (@PMLiVEcom)Photo by Pharmaceutical Market Europe (@PMLiVEcom)Photo by Pharmaceutical Market Europe (@PMLiVEcom)Photo by Pharmaceutical Market Europe (@PMLiVEcom)Photo by Pharmaceutical Market Europe (@PMLiVEcom)Photo by Pharmaceutical Market Europe (@PMLiVEcom)Photo by Pharmaceutical Market Europe (@PMLiVEcom)Photo by Pharmaceutical Market Europe (@PMLiVEcom)Photo by Pharmaceutical Market Europe (@PMLiVEcom)Photo by Pharmaceutical Market Europe (@PMLiVEcom)
MHRA approves new oral treatment for moderate-to-severe plaque psoriasis pmlive.com/pharma_news/mhra-…
MHRA approves new oral treatment for moderate-to-severe plaque psoriasis - PMLiVE

MHRA approves new oral treatment for moderate-to-severe plaque psoriasis - PMLiVE

Plaque psoriasis is an inflammatory condition that causes red, scaly and often itchy or painful patches of skin

pmlive.com
1
112
Novartis presents positive results from two phase 3 trials for relapsing MS pmlive.com/pharma_news/novar…
Novartis presents positive results from two phase 3 trials for relapsing MS - PMLiVE

Novartis presents positive results from two phase 3 trials for relapsing MS - PMLiVE

Remibrutinib reduced relapse rates and improved disease progression rates

pmlive.com
82
Spica Therapeutics appoints Jeff Abbey as CEO pmlive.com/pharma_appointmen…
Spica Therapeutics appoints Jeff Abbey as CEO - PMLiVE

Spica Therapeutics appoints Jeff Abbey as CEO - PMLiVE

Abbey most recently served as CEO of RNatives, where he is now Chairman of the Board

pmlive.com
126
New MHRA research published on needle-free Strep A vaccine pmlive.com/pharma_news/new-m…
New MHRA research published on needle-free Strep A vaccine - PMLiVE

New MHRA research published on needle-free Strep A vaccine - PMLiVE

There is currently no licensed vaccine for Strep A, despite it causing hundreds of millions of infections globally

pmlive.com
82
MAD World Summit 2026 secures official accreditation from The CPD Group pmlive.com/pharma_news/mad-w…
MAD World Summit 2026 secures official accreditation from The CPD Group - PMLiVE

MAD World Summit 2026 secures official accreditation from The CPD Group - PMLiVE

MAD World Summit takes place in London on 26 November at Convene, 155 Bishopsgate

pmlive.com
77
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer pmlive.com/pharma_news/roche…
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer - PMLiVE

Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer - PMLiVE

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

pmlive.com
2
147
Going private: what our year taught me about the patients pharma hasn’t yet spotted pmlive.com/pmhub/11_london/g…
Going private: what our year taught me about the patients pharma hasn’t yet spotted - PMLiVE

Going private: what our year taught me about the patients pharma hasn’t yet spotted - PMLiVE

A thought piece on the rise of private healthcare, and why brands should help new kinds of patients and HCPs

pmlive.com
107
INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar pmlive.com/pmhub/uniphar/inm…

INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreem...

Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

pmlive.com
93
Redefining Pediatric Epilepsy Care: Why We Must Move Beyond Symptom Suppression pmlive.com/pmhub/medscape_ed…
Redefining Pediatric Epilepsy Care: Why We Must Move Beyond Symptom Suppression - PMLiVE

Redefining Pediatric Epilepsy Care: Why We Must Move Beyond Symptom Suppression - PMLiVE

For families navigating pediatric epilepsy, the condition dictates every moment of their lives. The constant, crippling "anticipatory anxiety" of when the next seizure might hit transforms daily...

pmlive.com
129
What the Most Favored Nation (MFN) policy means for UK Pharma pmlive.com/pmhub/amiculum_li…
What the Most Favored Nation (MFN) policy means for UK Pharma - PMLiVE

What the Most Favored Nation (MFN) policy means for UK Pharma - PMLiVE

By Jed Avissar and Manca Povsic

pmlive.com
107
ANTHEM strengthens team with three appointments following Healthy Influence launch pmlive.com/pmhub/bedrock/ant…
ANTHEM strengthens team with three appointments following Healthy Influence launch - PMLiVE

ANTHEM strengthens team with three appointments following Healthy Influence launch - PMLiVE

Healthcare communications consultancy welcomes new talent as it invests in its next phase of growth

pmlive.com
136
AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo pmlive.com/pharma_news/abbvi…
AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo - PMLiVE

AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo - PMLiVE

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

pmlive.com
155
Who’s steering? Why pharma needs humans at the helm of AI pmlive.com/pharma_news/whos-…
Who’s steering? Why pharma needs humans at the helm of AI - PMLiVE

Who’s steering? Why pharma needs humans at the helm of AI - PMLiVE

Understanding how AI decisions are made, who owns the outcomes and how accountability travels across partners and platforms

pmlive.com
125
“We’ve been told we can’t touch AI” pmlive.com/pmhub/11_london/w…
"We've been told we can't touch AI" - PMLiVE

"We've been told we can't touch AI" - PMLiVE

It's not been a great few weeks for anyone trying to make the calm, sensible case for AI tools. Researchers have been quitting the big labs, including

pmlive.com
100
Your AI pilot works. That’s the problem. pmlive.com/pmhub/11_london/y…
Your AI pilot works. That's the problem. - PMLiVE

Your AI pilot works. That's the problem. - PMLiVE

What breaks when you scale it won't be the model. It'll be your data.

pmlive.com
84
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy pmlive.com/pmhub/genesis_res…
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical...

Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical...

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will reshape orphan...

pmlive.com
82
Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss pmlive.com/pharma_news/regen…
Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss -...

Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss -...

Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss

pmlive.com
147
The impact of AI and digital health on chronic diseases pmlive.com/pharma_news/the-i…
The impact of AI and digital health on chronic diseases - PMLiVE

The impact of AI and digital health on chronic diseases - PMLiVE

Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, but what impact is this having on the pharma industry?

pmlive.com
1
125
Regulatory complexity: the challenges of navigating the new normal pmlive.com/pharma_news/regul…
Regulatory complexity: the challenges of navigating the new normal - PMLiVE

Regulatory complexity: the challenges of navigating the new normal - PMLiVE

How functional service provider models are helping pharma adapt to regulatory uncertainty

pmlive.com
108
Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo pmlive.com/pharma_news/pfize…
Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo - PMLiVE

Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo - PMLiVE

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

pmlive.com
103
Load more